417 related articles for article (PubMed ID: 34757064)
1. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
Wat J; Barmettler S
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064
[TBL] [Abstract][Full Text] [Related]
2. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians.
Kampouri E; Walti CS; Gauthier J; Hill JA
Expert Rev Hematol; 2022 Apr; 15(4):305-320. PubMed ID: 35385358
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
4. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy.
Hill JA; Giralt S; Torgerson TR; Lazarus HM
Blood Rev; 2019 Nov; 38():100596. PubMed ID: 31416717
[TBL] [Abstract][Full Text] [Related]
5. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
Kim SJ; Yoon SE; Kim WS
Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
Schroeder BA; Jess J; Sankaran H; Shah NN
Curr Opin Hematol; 2022 Jul; 29(4):225-232. PubMed ID: 35787551
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
10. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K; Perales MA
Bone Marrow Transplant; 2022 Oct; 57(10):1477-1488. PubMed ID: 35840746
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
12. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
16. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
Gauthier J; Turtle CJ
Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
18. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.
Mucha SR; Rajendram P
Curr Oncol; 2023 May; 30(5):5003-5023. PubMed ID: 37232836
[TBL] [Abstract][Full Text] [Related]
19. A chimeric antigen receptor-based cellular safeguard mechanism for selective
Svec M; Dötsch S; Warmuth L; Trebo M; Fräßle S; Riddell SR; Jäger U; D'Ippolito E; Busch DH
Front Immunol; 2023; 14():1268698. PubMed ID: 38274808
[TBL] [Abstract][Full Text] [Related]
20. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
